METASTATIC OR UNRESECTABLE RB1-NEGATIVE LEIOMYOSARCOMA

Clinical trials for METASTATIC OR UNRESECTABLE RB1-NEGATIVE LEIOMYOSARCOMA explained in plain language.

Never miss a new study

Get alerted when new METASTATIC OR UNRESECTABLE RB1-NEGATIVE LEIOMYOSARCOMA trials appear

Sign up with your email to follow new studies for METASTATIC OR UNRESECTABLE RB1-NEGATIVE LEIOMYOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug trial offers hope for rare, Hard-to-Treat sarcoma

Disease control Not yet recruiting

This early-phase study tests a new drug called REC-617 in 15 people with a rare type of soft tissue cancer (leiomyosarcoma) that has spread or cannot be removed and has lost a key protein called RB1. The main goal is to check the drug's safety and see if it can help control the c…

Matched conditions: METASTATIC OR UNRESECTABLE RB1-NEGATIVE LEIOMYOSARCOMA

Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Jun 16, 2026 12:53 UTC

METASTATIC OR UNRESECTABLE RB1-NEGATIVE LEIOMYOSARCOMA

Get alerted when new METASTATIC OR UNRESECTABLE RB1-NEGATIVE LEIOMYOSARCOMA trials appear

New drug trial offers hope for rare, Hard-to-Treat sarcoma